Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-11006 in Sepsis-Induced ARDS
NCT03202394Phase 2Completed
- Sponsor
- BioMarck Pharmaceuticals, Ltd.
- Start
- Aug 2017
- Primary completion
- Mar 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing BIO-11006 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events at 28 days. Started Aug 2017; status: completed.
02
Drugs
BIO-11006
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03202394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202394.